Recent Updates
Recently added Catalysts
RARE Negative Sentiment Score: 25/100

Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE

Key Takeaway: ClaimsFiler has issued a reminder to investors in Ultragenyx Pharmaceutical Inc., informing them of a lead plaintiff application deadline for a class action lawsuit. This lawsuit stems from allegations that the company failed to disclose material information regarding its Phase III studies for setrusumab, which did not show a significant reduction in fracture rates for Osteogenesis Imperfecta. Following these results, Ultragenyx's share price experienced a sharp decline of about 42%. The case is ongoing in the Southern District of New York, and investors have until April 6, 2026, to take action.

Market Sentiment Analysis

CONCERNS & RISKS

  • Ultragenyx's Phase III studies for setrusumab failed to meet efficacy endpoints.
  • The company's share price dropped approximately 42% following the disappointing study results.
  • Investors are reminded of the lead plaintiff deadline in a class action lawsuit due to these disclosures.

Full Press Release Details

NEW ORLEANS, March 04, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 6, 2026 to file lead plaintiff applications in a securities class action lawsuit against Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NasdaqGS: RARE), if they purchased or otherwise acquired the Company’s shares between August 3, 2023 and December 26, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.
Ultragenyx investors should visit us at https://claimsfiler.com/cases/nasdaq-rare/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.
Ultragenyx and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On December 26, 2025, the Company announced the “results from the Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta” disclosing that both its Phase III Orbit and Cosmic studies failed to demonstrate that setrusumab triggered a statistically significant reduction in annualized fracture rates for patients with osteogenesis imperfecta, and, as a result the Company “is evaluating its planned operations and will promptly define and implement significant expense reductions.” On this news, the price of Ultragenyx’s shares fell approximately 42%, from $34.19 per share on December 26, 2025 to $19.72 per share on December 29, 2025.
The case is Steven Bailey v. Ultragenyx Pharmaceutical Inc., et al., No. 26-cv-01097.
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.
To learn more about ClaimsFiler, visit www.claimsfiler.com.

Tags

Securities Litigation

Frequently Asked Questions

What is the deadline to file lead plaintiff applications?

Investors must file lead plaintiff applications by April 6, 2026.

What is the class period for the Ultragenyx lawsuit?

The class period is from August 3, 2023, to December 26, 2025.

What triggered the drop in Ultragenyx's share price?

The share price dropped after the announcement of failed Phase 3 study results.

Where can Ultragenyx investors get more information?

Investors can visit https://claimsfiler.com/cases/nasdaq-rare/ for details.

Who are the lawyers handling the Ultragenyx case?

The law firm Kahn Swick & Foti, LLC is managing the legal case.

Last updated: Mar 5, 2026